Primary Myelofibrosis Clinical Trials in Paris
6 recruitingParis, France
Showing 1–6 of 6 trials
Recruiting
Phase 2
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Primary MyelofibrosisMyelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
GlaxoSmithKline68 enrolled33 locationsNCT06517875
Recruiting
Phase 1
A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Primary Myelofibrosis
Ajax Therapeutics, Inc.76 enrolled16 locationsNCT06343805
Recruiting
Phase 3
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Polycythemia VeraEssential ThrombocythemiaPrefibrotic/Early Primary Myelofibrosis+1 more
University Hospital, Brest1,308 enrolled42 locationsNCT05198960
Recruiting
Not Applicable
Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
Myeloproliferative NeoplasmEssential ThrombocythemiaPrimary Myelofibrosis, Prefibrotic Stage+1 more
University Hospital, Angers260 enrolled10 locationsNCT04942080
Recruiting
Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia Myelofibrosis
Swedish Orphan Biovitrum399 enrolled207 locationsNCT03165734
Recruiting
Phase 1Phase 2
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
MyelofibrosisPrimary MyelofibrosisPost-PV MF+1 more
Telios Pharma, Inc.70 enrolled19 locationsNCT05280509